^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Alkylating agent

    Related drugs:
    1d
    Acute Abdomen Secondary to Ileal Perforation As the Initial Presentation of Advanced Müllerian Malignancy With Hepatic Metastasis: A Case Report. (PubMed, Cureus)
    The patient received combination chemotherapy with gemcitabine, carboplatin, and bevacizumab, achieving a near-complete metabolic response. Immunohistochemistry plays a crucial role in identifying the primary tumor origin. Management requires a staged approach with emergency surgical intervention followed by multidisciplinary oncological treatment for optimal outcomes.
    Journal
    |
    PAX8 (Paired box 8)
    |
    Avastin (bevacizumab) • carboplatin • gemcitabine
    1d
    SLC28A3 expression and fludarabine-emergent autoimmune hemolytic anemia in chronic lymphocytic leukemia: A new player in an old equation. (PubMed, Biomol Biomed)
    This retrospective study investigated the relationship between baseline SLC28A3 expression levels, quantified via reverse-transcriptase polymerase chain reaction (qRT-PCR), and the incidence of AIHA in a cohort of CLL patients receiving fludarabine and cyclophosphamide (FC) therapy. These findings suggest that diminished baseline SLC28A3 expression may correlate with an elevated risk of fludarabine-emergent AIHA in CLL patients. Further validation through larger, prospective cohorts is essential to confirm the predictive utility of SLC28A3 expression for optimizing fludarabine-based therapeutic strategies.
    Journal
    |
    SLC28A3 (Solute Carrier Family 28 Member 3)
    |
    cyclophosphamide • fludarabine IV
    1d
    Metabolic activation of LDHA by ERRα represses inflammasome-dependent pyroptosis and promotes ovarian cancer chemoresistance. (PubMed, Cell Death Dis)
    Scanning electron microscopy, immunofluorescence, Western Blot, and other molecular functional assays show that the ERRα/LDHA axis drives lactate accumulation, downregulates inflammasome-related proteins (NLRP3, caspase-1, GSDMD and GSDMD-N), thereby suppressing pyroptosis and promoting resistance to cisplatin, carboplatin, and paclitaxel in ovarian cancer cells. Created in BioRender. Ren, Y. (2025) https://BioRender.com/qeh0dw8.
    Journal
    |
    LDHA (Lactate dehydrogenase A) • NLRP3 (NLR Family Pyrin Domain Containing 3)
    |
    LDH elevation
    |
    cisplatin • carboplatin • paclitaxel
    1d
    SILENCE: Efficacy and Safety of Non Invasive Vagal Stimulation to Prevent Chemotherapy-induced Nausea (clinicaltrials.gov)
    P=N/A, N=338, Recruiting, University Hospital, Tours | Trial completion date: May 2024 --> Sep 2028 | Trial primary completion date: Feb 2024 --> Jul 2028
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide
    1d
    KCD (Carfilzomib/Cyclophosphamide/Dexamethasone) Regimen for the Treatment of Newly Diagnosed POEMS Syndrome (clinicaltrials.gov)
    P2, N=20, Recruiting, Shanghai Changzheng Hospital
    New P2 trial
    |
    cyclophosphamide • carfilzomib
    1d
    Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis (clinicaltrials.gov)
    P1, N=22, Active, not recruiting, City of Hope Medical Center | Trial completion date: May 2026 --> Apr 2027 | Trial primary completion date: May 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    cyclophosphamide • melphalan • fludarabine IV
    2d
    CRIMSON-NE: Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells (clinicaltrials.gov)
    P1, N=45, Active, not recruiting, Baylor College of Medicine | Recruiting --> Active, not recruiting | N=27 --> 45 | Trial completion date: May 2040 --> Mar 2041
    Enrollment closed • Enrollment change • Trial completion date
    |
    CD7 (CD7 Molecule)
    |
    cyclophosphamide
    2d
    18-C-0125: T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma (clinicaltrials.gov)
    P1, N=35, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
    Trial completion
    |
    cyclophosphamide • fludarabine IV
    2d
    Clinical and immunological effects of adding cyclophosphamide to pomalidomide-dexamethasone in relapsed-refractory multiple myeloma: The randomized MUKseven trial. (PubMed, Br J Haematol)
    Pretreatment CD4+ T-cell levels were identified as a prognostic PFS marker. In summary, our results demonstrate significant effects of cycloaddition to Pd on response and T-cell composition.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    cyclophosphamide • dexamethasone • pomalidomide
    2d
    Clinically Amyopathic Dermatomyositis: Epidemiology, Clinical Presentation, Pathophysiology, Treatment, and Prognosis: A Systematic Review. (PubMed, Rheumatol Ther)
    CADM is a serious, complex disease with a distinct clinical and serological profile, requiring further conceptual refinement and multicenter studies to better characterize this DM phenotype.
    Review • Journal
    |
    IFIH1 (Interferon Induced With Helicase C Domain 1) • CRP (C-reactive protein)
    |
    Rituxan (rituximab) • cyclophosphamide • cyclosporine
    3d
    Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis (clinicaltrials.gov)
    P2, N=56, Recruiting, National Heart, Lung, and Blood Institute (NHLBI) | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial primary completion date
    |
    HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide
    3d
    An Exploratory Study of Lurbinectedin With Radiotherapy in SCLC With Single-lesion Progression After First Course Treatment (clinicaltrials.gov)
    P2, N=9, Active, not recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Jun 2027 | Trial primary completion date: Mar 2025 --> Dec 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Zepzelca (lurbinectedin)